PURPOSE Most patients with advanced pancreas cancer experience pain and must limit
their daily activities because of tumor-related symptoms. To date, no treatment has had a …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

Background Treatment with cetuximab, a monoclonal antibody directed against the epidermal
growth factor receptor, improves overall and progression-free survival and preserves the …

Background The combination of fluorouracil and leucovorin has until recently been standard
therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with …

Background Colon cancers with high-frequency microsatellite instability have clinical and
pathological features that distinguish them from microsatellite-stable tumors. We investigated …

Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth
factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods …

PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant
prostate cancer using relevant end points of palliation in a randomized controlled …

… Consultant/Advisory Role: Malcolm Moore, Eli Lilly. Stock Own- … Honoraria: Hans von der
Maase, Eli Lilly; Luigi Dogliotti, Eli Lilly; Malcolm Moore, Eli Lilly. For a detailed description …

Context Adjuvant fluorouracil has been shown to be of benefit for patients with resected
pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as …

Purpose Treatment with gemcitabine provides modest benefits in patients with metastatic
pancreatic cancer. The addition of erlotinib to gemcitabine shows a small but significant …